MedTrace Logo

Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures

NCT04851717 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-07-01

No results posted yet for this study

Summary

To assess the efficacy of intravenous remimazolam in inducing and maintaining suitable sedation levels for paediatric patients undergoing diagnostic and/or therapeutic procedures

Conditions

  • Pediatric ALL

Interventions

DRUG

Remimazolam

Remimazolam for intravenous sedation

Sponsors & Collaborators

  • Paion UK Ltd.

    collaborator INDUSTRY

  • Acacia Pharma Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
0 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-15
Primary Completion
2027-10-31
Completion
2027-10-31
FDA Drug
Yes

Countries

  • United States
  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04851717 on ClinicalTrials.gov